Martin Sipkoff
MANAGED CARE July 2008. ©MediMedia USA

Employers have implemented a number of methods to slow down prescription drug costs, but waiving copayments for chronic conditions has yet to enjoy widespread use

Last year the cost of prescription drugs was the single largest part of health cost increases to employers, according to a recently released survey by Mercer, a national consultancy. As a result, promoting the use of generics and the management of specialty drugs are top priorities to employers — and therefore to health plans and pharmacy benefit managers.

“Employers expect health plans to have strategies that help them control the rise in costs,” says Steven E. Wojcik, vice president for policy at the National Business Group on Health. “They look for aggressive, creative strategies.”

The Mercer survey found that last year prescription drug benefit costs rose 9.3 percent for employers with 500 or more employees. Overall medical costs rose 5.1 percent — a four-point spread. But that’s an improvement: In 2000, drug benefit costs rose 18.3 percent and health benefit costs rose 6.6 percent, a difference of about 12 points.

According to Watson Wyatt, another consultancy, health care costs are projected to rise about 7 percent this year. The increase in drug costs is expected to slow slightly, but remain significant. “Rising drug costs will remain a concern among employers,” says Wojcik.

“Innovative ways to help control costs have come into place,” says Lisa Zeitel, senior consultant and co-leader of Mercer’s managed pharmacy business. “Employers want to both encourage compliance through educational programs, which can have a positive effect on overall health care costs, and take steps to encourage the use of generics, which can specifically help control drug costs. They value a two-pronged approach.”

Techniques such as shifting costs to employees through higher copayments and deductibles have helped slow the increase of health costs for employers. But according to the Mercer survey, many employers “appear to have achieved as high a level of member cost-share as they deem appropriate and are exploring other ways to fine-tune the management of pharmacy costs.” Other surveys, such as one recently released by Hewitt Associates, agree with Mercer.

“This offers a challenge for employers and pharmacy benefit management companies in finding innovative ways to help control costs,” says Zeitel. “At the same time, employers want to make sure their employees have access to the drugs that can be most beneficial.”

The management of specialty or biotech drugs is increasingly important for employers. An increasing number say they have reviewed plan benefits and limits for specialty or biotech drugs (45 percent in 2007, up from 34 percent in 2005). It’s even higher among the largest employers at 68 percent (up from 51 percent in 2005). Another 30 percent of respondents said they plan to review plan benefits for specialty drugs in 2008.

Controlling costs

Among all drugs, Mercer found that traditional means of controlling costs do remain popular. For example, most employers continue to use tiered copayments for their prescription drug benefit.

But formulary design is evolving: About 5 percent of employers with 500 or more employees and 10 percent of those with 20,000 or more employees have implemented four- or even five-tier structures, the highest for so-called lifestyle drugs, such as for insomnia.

Coinsurance remains popular because it allows employers to share costs consistently with employees, even when drug prices increase or fluctuate. It also creates a greater degree of pricing transparency in that employees are more aware of the actual cost of the drugs they use, and therefore are more prone to develop strategies of their own to manage costs.

Mail order remains extremely popular. In more than three fourths of plans (77 percent), members are encouraged to use mail order through a reduced copayment. A small number penalize employees who don’t use mail-order plans for maintenance drugs: 6 percent require an additional copayment from members who continue to use retail pharmacies after a specified number of refills, and 10 percent have discontinued retail coverage altogether. Only 13 percent of respondents do not use any mail-order incentives or penalties.

Encouraging generics

The single most significant and powerful trend is generic utilization — and it will strengthen. “There is a large opportunity to lower costs now and over the next several years as some significant brand-name drugs become available as less-expensive generics,” including statins, according to the survey.

Mercer found that more employers are requiring members to pay the difference between a brand-name and a generic drug, in addition to the generic copayment, if they request a brand drug when a generic is available. This incentive is called “Dispensed as Written (DAW) 2,” and 49 percent of employers are now implementing it. Twenty-nine percent are using an even tougher version, known as DAW 1, which imposes the penalty even if the physician requests the brand drug. Use of these penalties is growing: Mercer reports that an additional 9 percent of respondents said they will implement DAW 1 and 10 percent of respondents said they will use DAW 2 within two years.

What remains comparatively unpopular is free drugs for patients with chronic conditions, although this idea has received some publicity. Employers were asked if they are providing financial incentives, either through lowering or waiving drug copayments or coinsurance, for specific drug therapies in order to encourage medication compliance. Only 4 percent of employers waived generic copayments.

Mercer found that only 6 percent of employers use any financial incentive for diabetes treatment, the largest percentage in any therapeutic category, but 26 percent of employers are considering implementing such a policy for diabetes therapy and about a fourth are considering the same approach for other therapeutic classes used to treat chronic conditions.

“Employers seek innovative compliance techniques,” says Zeitel. “That trend will continue, certainly.”

Contributing Editor Martin Sipkoff is a long-time health care journalist.

More information about the two surveys discussed above is available at www.mercer.com and www.hewittassociates.com.













Employers take a variety of actions to help control costs

A recent Mercer survey found that employers are most likely to promote generics as a cost management tool in their pharmacy benefit. Among the strategies:

Likely actions of employers in cost and quality management of drug benefits

“Very likely” or “likely” to take action

Promote greater utilization of generic alternatives

Improve management of specialty drugs under the prescription drug program

Increase employee copayment or coinsurance amounts

Implement patient medication therapy adherence/compliance programs

Implement an on-site or near-site pharmacy for employees

Source: Hot Topics In Health Care Pharmacy Benefits, Mercer

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.